Review Article

US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives

Shawn Shouye Wang¹,* , Yifei (Susie) Yan² and Kin Ho¹

¹CMC Management, WuXi Biologics, 1 Cedarbrook Drive, Cranbury, NJ 08512, USA, and ²Biologics CMC Leadership training program, WuXi Biologics, Palo Alto, CA, USA

Received: July 1, 2021; Revised: September 6, 2021; Accepted: November 8, 2021

ABSTRACT

Thirty four (34) of the total US FDA approved 103 therapeutic antibody drugs, accounts for one third of the total approved mAbs, are formulated with high protein concentration (100 mg/mL or above) which are the focus of this article. The highest protein concentration of these approved mAbs is 200 mg/mL. The dominant administration route is subcutaneous (76%). Our analysis indicates that it may be rational to implement a platform formulation containing polysorbate, histidine and sucrose to accelerate high concentration formulation development for antibody drugs. Since 2015, the FDA approval numbers are significantly increased which account for 76% of the total approval numbers, i.e., 26 out of 34 highly concentrated antibodies. Thus, we believe that the high concentration formulations of antibody drugs will be the future trend of therapeutic antibody formulation development, regardless of the challenges of highly concentrated protein formulations.

Statement of Significance Thirty four therapeutic antibodies approved by the US FDA with high-protein concentration formulation (100 mg/mL or above) are analyzed.

KEYWORDS: therapeutic antibodies; high concentration; formulation; US FDA; subcutaneous; approval; dosage; administration route; formulation composition; pre-filled syringe; lyophilization; excipient

INTRODUCTION

The first US FDA-approved monoclonal antibody (mAb) drug (approved in 1986 for marketing) is muromonab-CD3 (Orthoclone OKT3) with low protein concentration formulation at only 1 mg/mL (1). Ever since, as of October 2021, FDA has approved 103 therapeutic antibody drugs including antibody-based therapeutics such as antibody drug conjugates in the past 35 years for marketing (2). Most of these 103 antibody drugs are formulated with low protein concentrations (<50 mg/mL) partially because of technical challenges in developing high-concentration formulation for antibody drugs. These technical challenges have been discussed and reviewed in several excellent review articles and book chapters (3–7). More than one decade later after FDA approved the first mAb, FDA approved in 1998 the first mAb formulated with 100 mg/mL protein concentration (Synagis, Palivizumab) (8). While drafting this article, we notice that an excellent review of formulations of commercially available antibodies approved by global regulatory agencies was already published in March 2021 (9). Our article, as indicated in the title, is focused only upon the US FDA-approved therapeutic antibodies with high-concentration formulation.
Developing therapeutic antibodies with high-concentration formulation is now highly demanded in biopharmaceutical industry because of the following several reasons. This demand is partially driven by increasing subcutaneous (SC) administration for antibodies approved for commercial and/or late clinical stage. Other reasons are to extend shelf life and patent protection period of approved biologics with increased protein concentration (10). One of the examples is Merck & Co. (MSD)’s Keytruda (pembrolizumab), which was initially approved by the US FDA in 2014 for marketing. This is a lyophilized product, and can be reconstituted at 25 mg/mL protein concentration. Merck & Co. started several years ago to develop high concentration formulation for SC administration for its already marketed Keytruda. Merck reported most recently the phase I clinical trial results of Keytruda with SC delivery at the 2021 Annual Meeting of the American Association for Cancer Research (AACR abstract #: CT143) (11).

Therapeutic antibodies with high-concentration formulation can also offer other benefits, such as suitable for advanced administration (for instance self-administration with auto-injection devices). Therefore, reduction in administration time and medical resource utilization benefits both patients (especially for those with chronic diseases) and the entire healthcare system (12).

It is rarely defined how high is the high-concentration formulation (13). General speaking, equal to and more than 100 mg/mL protein concentration is widely regarded as high-concentration formulation and lower than 50 mg/mL is typically regarded a low concentration formulation. However, the range in between 50 and 100 mg/mL is usually a controversial grey range. Thus, in this review article we set ≥100 mg/mL as a criteria of high-concentration formulation for our data analysis. Based upon the publicly available information (dominantly from FDA website), we comprehensively analyzed the 34 FDA-approved therapeutic antibodies with at least 100 mg/mL protein concentration (as of October 2021). The raw data of these 34 antibody drugs are compiled in Table 1. The analysis of these data shown in Table 1 includes (a) FDA approval number versus approved year, (b) formulation composition analysis, (c) dosage form, (d) concentration analysis, (e) administration route analysis, (f) top sponsors of FDA-approved therapeutic antibodies with high-concentration formulation and (g) IgG type. In this article, we discussed some interesting and/or unexpected conclusions. We also proposed our own perspectives and insights based upon these results, and trends from the data analysis.

**SUMMARIES**

**FDA approval number vs. approval year**

As shown in Fig. 1, the FDA approval numbers are significantly increased since 2015. The approval number since 2015 (twenty six) accounts for 76% of the total approval number (thirty four), suggesting the increasing demand of high-concentration formulation in recent years from biopharmaceutical industry.

**Formulation excipient analysis**

The formulation excipients of the 34 therapeutic antibodies approved by the US FDA with high-concentration formulation were analyzed. The frequency of the formulation excipients used in each formulation composition in these 34 antibodies were calculated, and only formulation excipients with greater than 5% frequency are presented in Fig. 2. The major formulation excipients with more than 10% frequency are polysorbate (94%, including both polysorbate 20 and polysorbate 80), histidine (82%), sucrose (48%), arginine (27%), sodium chloride (NaCl, 18%), methionine (18%), acetate (12%) and trehalose (12%). Other formulation excipients with less than 10% frequency are proline, sorbitol, sodium phosphate, poloxamer 188, ethylenediaminetetraacetic acid (EDTA), citric acid, mannitol, glutamate, glycine, sodium citrate, sodium succinate and lactic acid.

**Dosage form presentation**

As demonstrated in Fig. 3, the dosage forms of the 34 antibodies with high-concentration formulation may be categorized as the following: liquid solution (Liq) only, lyophilized powder (Lyo), pre-filled syringe (PFS) only, and both PFS and Lyo. Please note that Liq dosage form is liquid in a vial, and the PFS represents also liquid but in pre-filled syringe. The Liq and the PFS presentations take up predominantly the market shares at 43% and 39%, respectively, followed by both PFS and Lyo at 12%. Unexpectedly, only 6% (2 products) of these 34 antibodies are formulated as lyophilized powders (Lyo) only.

Recent trends in the pharma injectable market have been observed such as a shift to self-medication to enhance patient convenience; tightened regulatory scrutiny and quality requirements for patient safety; and continuous exploration in patient experience and compliance. These trends are linked to an increased demand on the easy-to-use delivery devices such as prefilled syringes (PFS) (14–16). Additionally, after 2015, the FDA-approved high-concentration antibody products have been all either in liquid in vial or liquid in PFS format.

**Concentration analysis**

We analyzed the protein concentration in two concentration ranges, i.e., 100–150 mg/mL, which includes the lower limit of 100 mg/mL, but not the upper limit of 150 mg/mL; and 150–200 mg/mL, which includes both the lower limit of 150 mg/mL and the upper limit of 200 mg/mL. The formulations in the range of 100–150 mg/mL (56%) are slightly more than those of 150–200 mg/mL (44%). The highest protein concentration is at 200 mg/mL from products Benlysta (Belimumab) and Cimzia (Certolizumab pegol).

**Administration route analysis**

The Administration routes of the 34 antibodies with high-concentration formulation consist of four types: intravitreal injection (IVI), intravenous (IV), intramuscular (IM) and subcutaneous (SC). As shown in Fig. 4,
| Product name                        | Dosage form | Antibody concentration (mg/mL) | IgG Type | Formulation (per mL for liquid formulation if not specified)                                                                 | Indication                                                                 | Approved year | Administration route | Sponsor                  |
|------------------------------------|-------------|--------------------------------|----------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|----------------|----------------------|--------------------------|
| Suvzimo (Ranibizumab)              | Liquid      | 100                            | IgG1     | 1 mg/mL L-histidine HCl, 0.1 mg/mL polysorbate 20, 32 mg/mL sucrose, pH 5.5                                                 | Neovascular (wet) age-related macular degeneration (AMD)                     | 2021           | IVI                  | Roche/Genentech          |
| Adalimumab (Adalimumab-awwa)       | Liquid      | 100                            | IgG1     | 31.60 mg/mL L-arginine hydrochloride, 0.60 mg/mL L-histidine, 3.39 mg/mL L-histidine hydrochloride monohydrate, 1.49 mg/mL L-methionine, 0.50 mg/mL polysorbate 80, pH 5.5 | Alzheimer’s disease                                                        | 2021           | IV                   | Biogen and Eisai         |
| Evkzerza (Evinacumab-dgmb)         | Liquid      | 150                            | IgG4     | 14.8 mg/mL L-arginine hydrochloride, 0.74 mg/mL L-histidine, 1.1 mg/mL L-histidine hydrochloride monohydrate, 0.4 mg/mL polysorbate 80, pH 5.5 | Homozygous familial hypercholesterolemia                                   | 2021           | IV                   | Regeneron                |
| Enspryng (Satumumab-bwge)          | PFS         | 120                            | IgG2     | 26.1 mg/mL L-arginine, 3.1 mg/mL L-histidine, 0.5 mg/mL polysorbate 80, 40.5 mg/mL sorbitol, pH 5.8                        | Neuromyelitis optica spectrum disorder                                      | 2020           | SC                   | Genentech                |
| PHESGO (Pertuzumab and Hyaluronidase-xyz) | Liquid | 120 (600 mg each) | IgG1     | 2000 Units hyaluronidase, 39.7 mg/mL α, α-trehalose, 0.44 mg/mL L-histidine, 3.61 mg/mL L-histidine hydrochloride monohydrate, 1.49 mg/mL L-methionine, 0.4 mg/mL polysorbate 20, 79.45 mg/mL α, α-trehalose dihydrate, pH 5.5 | 1. Early breast cancer (EBC) 2. Metastatic breast cancer (MBC)              | 2020           | SC                   | Genentech                |
| Vyepti (Eptinezumab-jmre)           | Liquid      | 100                            | IgG1     | 1 mg/mL L-histidine, 2.8 mg/mL L-histidine hydrochloride monohydrate, 0.15 mg/mL polysorbate 80, 40.5 mg/mL sorbitol, pH 5.5 | Migraine                                                                   | 2020           | IV                   | Lundbeck                 |
| Bevus (Broculosumab-dbli)           | Liquid      | 120                            | scFv     | 0.02% Polysorbate 80, 10 mM sodium citrate, 5.3% sucrose, pH 7.2                                                          | Neovascular (wet) AMD                                                      | 2019           | IVI                  | Novartis                 |
| Hereplin Hylecta (Trastuzumab and Hyaluronidase-oys) | Liquid | 120 | IgG1     | 2000 Units hyaluronidase, 0.39 mg/mL L-histidine, 3.67 mg/mL L-histidine hydrochloride monohydrate, 1.49 mg/mL L-methionine, 0.4 mg/mL polysorbate 20, 79.45 mg/mL α, α-trehalose dihydrate, pH 5.5 | HER2-overexpressing breast cancer                                           | 2019           | SC                   | Genentech                |
| Aimovig (Eromacumab-uooe)           | PFS         | 140 (70 also available)         | IgG2     | 2.0 mg/mL 0.025 M acetate, 0.10 mg/mL polysorbate 80, 65 mg/mL sucrose, pH 5.2                                            | Migraine                                                                   | 2018           | SC                   | Amgen/Novartis           |
| Ajovy (Fremacumab-vfml)             | Liquid      | 150                            | IgG2     | 0.136 mg/mL disodium ethylenediaminetetraacetic acid dihydrate (EDTA), 0.543 mg/mL L-histidine, 2.62 mg/mL L-histidine hydrochloride monohydrate, 0.2 mg/mL polysorbate 80, 66 mg/mL sucrose, pH 5.5 | Migraine                                                                  | 2018           | SC                   | TEVA PHARMS USA          |
| Engalix (Gakaneumab-gnml)           | PFSpret-filled pen | 120 | IgG4     | 0.5 mg/mL L-histidine, 1.5 mg/mL L-histidine hydrochloride monohydrate, 0.5 mg/mL polysorbate 80, 8.8 mg/mL sodium chloride, pH 5.8 | 1. Migraine 2. Episodic cluster headache                                   | 2018           | SC                   | Eli Lily                 |
| Ilumya (Tildikizumab-asmm)          | PFS         | 100                            | IgG1     | 0.495 mg/mL L-histidine, 1.42 mg/mL L-histidine hydrochloride monohydrate, 0.5 mg/mL polysorbate 80, 70.0 mg/mL sucrose, pH 5.7-6.3 | Plaque psoriasis                                                           | 2018           | SC                   | Sun Pharma Global        |
| Tekhyro (Lanadulumab-fbo)           | Liquid      | 150                            | IgG1     | 4.1 mg/mL citric acid monobeharate, 7.8 mg/mL L-histidine, 0.1 mg/mL polysorbate 80, 5.3 mg/mL sodium chloride, 5.3 mg/mL sodium phosphate dibasic dihydrate, pH 6 | Hereditary angioedema                                                      | 2018           | SC                   | Dyax Corp                |
| Trogavzo (Ilalizumab-ayk)           | Liquid      | 150                            | IgG4     | 10 mg/mL L-histidine, 0.045% polysorbate 80, 52 mM sodium chloride, 5.2% sucrose, pH 6                                     | HIV                                                                        | 2018           | IV                   | THERA                    |
| Dupixent (Dupilumab)                | PFS         | 150                            | IgG4     | 5.25 mg/mL L-arginine hydrochloride, 3.1 mg/mL L-histidine, 2 mg/mL polysorbate 80, 1 mg/mL sodium acetate, 50 mg/mL sucrose, pH 5.9 | 1. Atopic dermatitis 2. Asthma 3. Chronic rhinosinusitis with nasal polyposis | 2017           | SC                   | Regeneron/Sanoﬁ          |

(Continued)
| Product name | Dosage form | Antibody concentration (mg/mL) | IgG Type | Formulation (per mL for liquid formulation if not specified) | Indication | Approved year | Administration route | Sponsor |
|--------------|-------------|--------------------------------|----------|---------------------------------------------------------------|-----------|---------------|---------------------|---------|
| Hemlibra (Emicizumab-kxwh) | Liquid | 150 | IgG4 | 26.1 mg/mL L-arginine, 3.1 mg/mL L-histidine, 0.5 mg/mL poloxamer 188, pH 6 | 1. Hemophilia A | 2017 | SC | Genentech |
| Kevzara (Sarilumab) | PFS/pre-filled pen | 131/175 | IgG | 7.84 mg/mL Arginine, 3.25 mg/mL L-histidine, 2 mg/mL polysorbate 20, 50 mg/mL sucrose, pH 6 | Rheumatoid arthritis | 2017 | SC | Sanofi |
| Rituxan Hycela (Rituximab and Hyaluronidase human) | Liquid | 120 | IgG1 | 2000 Units hyaluronidase, 0.53 mg/mL L-histidine, 3.47 mg/mL L-histidine hydrochloride monohydrate, 1.49 mg/mL L-methionine, 0.6 mg/mL polysorbate 80, 79.45 mg/mL α, α-trehalose dihydrate, pH 5.5 | 1. Follicular lymphoma 2. Diffuse large B-cell lymphoma 3. Chronic lymphocytic leukemia | 2017 | SC | Genentech |
| Siliq (Brodalumab) | Liquid | 140 | IgG2 | 4.3 mg/mL glutamate, 0.1 mg/mL polysorbate 20, 24 mg/mL proline, pH 4.8 | Plaque psoriasis | 2017 | SC | Valeant Pharmaceuticals |
| Tremfya (Guselkumab) | PFS | 100 | IgG1 | 0.6 mg/mL L-histidine, 1.5 mg/mL L-histidine monohydrochloride monohydrate, 0.5 mg/mL polysorbate 80, 79 mg/mL sucrose, pH 5.5 | Plaque psoriasis | 2017 | SC | Janssen |
| Anthim (Obiltoxaximab) | Liquid | 100 | IgG1 | 6.2 mg/mL L-histidine, 0.1 mg/mL polysorbate 80, 36 mg/mL sorbitol, pH 5.5 | Anthrax infection | 2016 | IV | Elusys Therapeutics |
| Cosentyx (Secukinumab) | 1. PFS 2. Lyophilized | 150 | IgG1 | 1. 3.103 mg/mL L-histidine/histidine monohydrochloride, 0.746 mg/mL L-methionine, 0.2 mg/mL polysorbate 80, 75.67 mg/mL trehalose dihydrate, pH 5.8. 2. After reconstitution with 1 mL WFI: 4.656 mg/mL L-histidine/histidine monohydrochloride, 0.6 mg/mL polysorbate 80, 92.43 mg/mL sucrose, pH 5.8 | 1. Plaque Psoriasis 2. Psoriatic arthritis 3. Ankylosing spondylitis 4. Non-radiographic Axial spondyloarthritis | 2015 | SC | Novartis |
| Nucala (Mepolizumab) | 1. PFS 2. Lyophilized | 100 | IgG1 | 1. 0.95 mg/mL Citric acid monohydrate, 0.019 mg/mL EDTA disodium dihydrate, 0.2 mg/mL polysorbate 80, 4.16 mg/mL sodium phosphate dibasic heptahydrate, 120 mg/mL sucrose, pH 6.3. 2. After reconstitution with 1.2 mL WFI: 0.67 mg/mL polysorbate 80, 7.14 mg/mL sodium phosphate dibasic heptahydrate, 160 mg/mL sucrose, pH 7 | 1. Severe asthma 2. Eosinophilic granulomatosis with polyangiitis 3. Hyper eosinophilic syndrome | 2015 | SC | GlaxoSmithKline |
| Praluent (Alirocumab) | PFS | 150 (75 also available) | IgG | 6.0 mg/mL Histidine, 0.1 mg/mL polysorbate 20, 100 mg/mL sucrose, pH 6 | 1. Primary hyperlipidemia 2. CV Disease 3. Homozygous familial hypercholesterolemia | 2015 | SC | Sanofi |
| Repatha (Evolocumab) | PFS | 140 | IgG2 | 1.2 mg/mL Acetate, 0.1 mg/mL polysorbate 80, 25 mg/mL proline, pH 5 | 1. Dyslipidemias 2. Hypercholesterolemia | 2015 | SC | Amgen |
| Benlysta (Belimumab) | PFS | 200 | IgG1 | 5.3 mg/mL L-arginine hydrochloride, 0.65 mg/mL L-histidine, 1.2 mg/mL L-histidine monohydrochloride, 0.1 mg/mL polysorbate 80, 6.7 mg/mL sodium chloride, pH 6 | Systemic lupus erythematosus | 2011 | SC | GlaxoSmithKline |
| Actemra (Tocilizumab) | PFS | 180 | IgG1 | 0.2 mg/mL polysorbate 80, 1.7 mg/mL L-histidine, 1.9 mg/mL L-histidine monohydrochloride, 2L mg/mL L-arginine and L-arginine hydrochloride, 4.4 mg/mL L-methionine, pH 6 | 1. RA 2. GCA 3. Polymyositis juvenile idiopathic arthritis (PJA) 4. Systemic juvenile idiopathic arthritis (SJIA) 5. Cytokine release syndrome (CRS) | 2010 | SC | Chugai (Roche) |
| Ilaris (Canakinumab) | 1. Lyophilized 2. Liquid | 150 | IgG1 | 1. Lyophilized powder after reconstitution with 1 mL WFI: 2.8 mg/mL L-histidine, 1.7 mg/mL L-histidine monohydrochloride, 0.6 mg/mL polysorbate 80, 92.4 mg/mL sucrose. 2. Liquid solution 2.1 mg/mL L-histidine, 1.3 mg/mL L-histidine monohydrochloride, 49.2 mg/mL mannitol, 0.4 mg/mL polysorbate 80. | 1. Periodic fever syndromes 2. Still's disease | 2009 | SC | Novartis |
| Product name       | Dosage form | Antibody concentration (mg/mL) | Anti-body concentration | Formulation (per mL for liquid formulation if not specified) | Indication                                      | Approved year | Administration route | Sponsor       |
|-------------------|-------------|--------------------------------|-------------------------|--------------------------------------------------------------|------------------------------------------------|--------------|---------------------|---------------|
| Simponi (Golimumab) | PF/S        | 100                            | IgG1                    | 0.88 mg/mL L-histidine and L-histidine monohydrochloride, 0.16 mg/mL polysorbate 80, 41 mg/mL sorbitol, pH 5.5 | 1. RA 2. Psoriatic Arthritis 3. Ankylosing spondylitis | 2009         | SC                  | Janssen       |
| Cimzia (Certolizumab pegol) | 1. PF/S, 2. Lyophilized | 200                            | Fab                    | 1. PF/Solution 1.36 mg/mL sodium acetate, 7.3 mg/mL sodium chloride, pH 4.7. 2. Lyophilized powder after reconstitution with 1 mL WFI: 0.9 mg/mL lactic acid, 0.1 mg/mL polysorbate, 100 mg/mL sucrose, pH 5.2 | 1. Crohn's disease 2. RA 3. Psoriatic arthritis 4. Ankylosing spondylitis 5. Non-radiographic Axial spondylitis 6. Plaque psoriasis | 2008         | SC                  | UCB           |
| Raptiva (Efalizumab) | Lyophilized | 100                            | IgG1                    | After reconstitution with 1 mL WFI: 82.1 mg/mL sucrose, 4.5 mg/mL L-histidine hydrochloride monohydrate, 2.9 mg/mL L-histidine, 2 mg/mL polysorbate 20, pH 6.2 | Psoriasis | 2003         | SC                  | Merck Serono/Genetech |
| Xolair (Omalizumab) | 1. PF/S, 2. Lyophilized | 150, 125                        | IgG1                    | 1. PF/Solution 42.1 mg/mL L-arginine hydrochloride, 1.37 mg/mL L-histidine, 2.34 mg/mL L-histidine hydrochloride monohydrate, 0.4 mg/mL polysorbate 20, 2. Lyophilized powder After reconstitution with 1.4 mL WFI: 1.08 mg/mL L-histidine, 1.75 mg/mL L-histidine hydrochloride monohydrate, 0.33 mg/mL polysorbate 20, 90 mg/mL sucrose, pH 6.0 | 1. Asthma 2. Nasal polypos 3. Chronic idiopathic urticaria (CIU) | 2003         | SC                  | Novartis/Genetech |
| Synagis (Palivizumab) | Liquid      | 100                            | IgG1                    | 0.5 mg/mL chloride, 0.1 mg/mL glycine, 3.5 mg/mL histidine, pH 6.0 | Prophylaxis of Respiratory diseases | 1998         | IM                  | MedImmune     |

The pH values of the lyophilized antibodies in the table are referred to the pHs in reconstituted antibody solutions. The pH of reconstituted Ilaris (Canakinumab) is not available from the public available information. The pH of reconstituted Ilaris is calculated as around approximately 6.3, based upon the disclosed formulation excipients of this product.

IVI: Intravitreal injection; IV: intravenous; IM: intramuscular; SC: subcutaneous; scFv: single chain variable fragments; Fab: fragment antigen binding. WFI: water for injection.
Figure 1. Yearly US FDA approval numbers of therapeutic antibodies with high-concentration formulation during 1998–2021. The 2021 year’s data are as of October 2021. Only antibodies with ≥100 mg/mL protein concentration are counted in the data analysis. The first therapeutic antibody with high-concentration formulation (i.e., Synagis/Palivizumab, 100 mg/mL) was approved by US FDA in 1998. Thus, the data analysis in Fig. 1 was started from 1998.

Figure 2. Formulation excipient analysis of US FDA-approved therapeutic antibodies with high-concentration formulation. The formulation excipients of 34 therapeutic antibodies approved by US FDA with high-concentration formulation were analyzed. The frequency of each formulation composition in these 34 antibodies were calculated, and only formulation excipients with more than 5% frequency were presented in Fig. 2.

the dominant administration route, as expected, is SC (26 products, 76%), followed by IV (5 products, 15%), IVI (2 products, 6%) and IM (1 product, 3%). The only antibody with IM administration route is Synagis (Palivizumab) which is, as mentioned above, the first FDA-approved high-concentration antibody product. The two IVI-administered antibody products are Beovu (Brolucizumab-dbll), and Susvimo (Ranibizumab), which the latter was approved in October, 2021 by US FDA for intravitreal use via ocular implant for the treatment of patients with neovascular or “wet” age-related macular degeneration (nAMD). Although both Beovu and
Susvimo share the same indication (nAMD) and the same administration route (IVI), Susvimo (Ranibizumab) is delivered by a special system. This system is called Port Delivery System (PDS) which can continuously deliver the Ranibizumab medicine into the eyes through a refillable implant. Thus with just as few as two treatments per year, Susvimo could help patients with nAMD maintain their vision.

In addition, the above-mentioned antibody products with either IV, or IVI or IM administration routes are all in liquid dosage form, as shown in Table 1.

**Top sponsors of FDA-approved therapeutic high-concentration antibodies**

We also analyzed the sponsors of the 34 antibodies to identify the top players in high-concentration formulation segment of the industry. If two companies are the co-sponsors of an antibody, each of the two sponsors is counted with a 0.5 approval number. We propose to categorize these sponsors as three different tiers, i.e., tier 1 (8 approved products), tier 2 (1.5–4 approved products) and tier 3 (0.5–1 approved product). Only Roche and its subsidiaries (Genentech and Chugai) fall in the tier 1 category with 8 approved antibodies at high-concentration

(including two approved antibodies co-sponsored with other companies). This Roche’s approval number (eight) is far greater than any other sponsors’ approval numbers. The tier 2 sponsors with approval numbers ranging from 1.5 to 4 include Novartis (4 approvals), Sanofi (2.5 approvals), Amgen (2 approvals), GSK (2 approvals), Johnson & Johnson including its subsidiary Janssen (2 approvals), Regeneron (1.5 approvals) and Biogen (1.5 approvals), as shown in Fig. 5. All other sponsors with a single or 0.5 approval, have gone to the tier 3 sponsor category.

**IgG type**

Not surprisingly, most of the 34 antibodies are IgG1 (22 out of 34), followed by IgG2 (5 out of 34), IgG4 (5 out of 34) and other IgG types (2 out of 34). Other IgG types include single-chain variable fragments (scFv, Beovu/Brolucizumab-dbll), and fragment antigen binding (Fab, Cimzia/Certolizumab pegol).

**DISCUSSION AND PERSPECTIVES**

Thanks to the technical advances in high-concentration formulation, our data in Fig. 1 clearly demonstrate an increasing trend of the FDA approval numbers of high-concentration antibody drugs in recent years. This trend is partially driven by clinicians and patients, as discussed in literature (12). Both clinicians and patients demand an SC delivery of antibody drugs because the SC injection is more convenient than the IV injection and yet less expensive. Such antibody drugs with high-concentration formulation may be administrated in clinic or even at patients’ homes. However, developing high-concentration formulation of the antibody drugs for SC administration is not an easy task because of many challenges (e.g., limitation of 1–2 mL injection volume) (16, 19). We believe that the establishment of SC Drug Delivery and Development Consortium in 2018 accelerated progress on addressing these challenges associated with SC drug delivery and high-concentration
formulation of antibody drugs (18, 20). Eight problem statements were indeed proposed by this SC Consortium, which aim to identify and then address the critical gaps and issues in the SC delivery of high-dose/volume products (18). The SC Consortium also highlighted the needs to shift perceptions of the capabilities of technologies that enabled the SC delivery of large-volume (> 3 mL) and/or high-dose biologics. Most of the key members of the SC Consortium are from big biopharmaceutical companies such as Pfizer, Sanofi, Amgen, Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Johnson & Johnson Company, Novartis and Merck, nearly all of which are the sponsors of the FDA-approved high-concentration antibodies (except Pfizer), as shown in Fig. 5.

In addition to the technical advances in SC delivery as summarized in the review articles (16, 21–24), the recombinant human hyaluronidase (rHuPH20) developed by Halozyme may dramatically increase the SC injection volume (up to hundreds of milliliters) (25, 26). Halozyme can degrade hyaluronan (HA), a glycan that fills the interstitial space within the collagenous matrix and acts as a physical barrier to prevent bulk fluid flow, and therefore facilitates the dispersion and absorption of the drug and fluids that are injected under the skin. Three out of the 34 antibody drugs with high-concentration formulation listed in Table 1 are indeed co-formulated with recombinant human hyaluronidase, i.e., Phesgo (Pertuzumab, Trastuzumab and Hyaluronidase-xxxf), Herceptin Hylecta (Trastuzumab and hyaluronidase-ousk) and Rituxan Hycela (Rituximab and Hyaluronidase human). All of these three above mentioned antibody drugs were developed and sponsored by Genentech/Roche under the collaboration with Halozyme. It is noteworthy that Phesgo contains two different antibodies, i.e., Pertuzumab and Trastuzumab. This is the first two-in-one cocktail antibody drug approved by FDA in 2020 for the treatment of breast cancer (27).

As shown in Table 1, a typical antibody formulation of the 34 antibody therapeutics consists of an antibody, a buffer and a surfactant, as well as an excipient to adjust toxicity or osmolality for solutions or a lyoprotectant for lyophilized powder. Other commonly used excipients in formulation compositions are sodium chloride, an ionic tonicity-adjusting excipient, and the non-ionic osmolality-adjusting excipients such as sucrose, trehalose, and sorbitol. Sucrose and trehalose are stabilizer and could be used as the lyoprotectants in amorphous formulations. The pH range of the 34 formulations is 4.7–7.2. The lowest pH 4.7 is found in the solution of Cimzia (Certolizumab pegol)’s PFS. Interestingly, as shown in Table 1, the formulations and the corresponding pHs of Cimzia’s two dosage forms between PFS and lyophilized powder are different. The formulation of Cimzia’s solution in PFS is 1.36 mg/mL sodium acetate, 7.3 mg/mL sodium chloride, pH 4.7, while the formulation of reconstituted lyophilized powder is 0.9 mg/mL lactic acid, 0.1 mg/mL polysorbate, 100 mg/mL sucrose, pH 5.2. The highest pH 7.2 is in the solution of Beovu (Brolucizumab-dbll).

Furthermore, the buffering systems of the 34 formulated antibodies are quite diverse, but histidine-HCl is the dominant buffer used (82% of all formulations). Other buffers or pH-modifying agents include citrate, succinate, acetate, phosphate, glutamate, aspartic acid and lactic acid. Based upon the above discussion, it would be rational to build a platform formulation that basically contains polysorbate, histidine and sucrose in order to accelerate the timeline and to enhance the efforts/efficiency on high-concentration formulation development for antibody drugs, especially at early stage.

Consistent with our observation, Robert Strickley and William Lambert suggested this year (2021) in their review article that “a typical subcutaneous solution formulation has 100 mg/mL antibody, sucrose at 50 mg/mL, buffered at pH 6 by 0.01M histidine, has the surfactant polysorbate 80 at 0.01 mg/mL, the viscosity lowered with 10 mg/mL arginine, and is packaged in a prefilled syringe” (9).

As discussed above, all the excipients in Table 1 are traditional and these have been used in the approved antibody drugs for many years. Thus far, no novel excipients have been used in any of the FDA-approved high-concentration antibody products for a few decades mainly because of the difficulty in getting approved by FDA (12). Interestingly, FDA’s Center for Drug Evaluation and Research (CDER) launched in September 2021 the voluntary Novel Excipient Pilot Program (Pilot Program), which is intended to “allow excipient manufacturers to obtain FDA review of certain novel excipients prior to their use in drug formulations” (visit https://www.fda.gov/drugs/development-aapproval-process-drugs/novel-excipient-review-pilot-program for more detailed information). We expect that this Pilot Program and strategy would foster the development of novel excipients, followed by the application of these excipients in drug product development.

Two notorious technical challenges associated with high-concentration formulation are high viscosity and aggregation (29–31, 38–40). It is now well established that the viscosity of an antibody solution may increase exponentially with the increasing antibody concentration. Thus, the high viscosity of the high-concentration antibody may result in challenges during manufacturing the drug substance (especially ultrafiltration and diafiltration process) and the drug product (in particular mixing, sterile filtration and filling). If subcutaneous administration is used for administration of high-viscosity antibody drug, large bore size needles may have to be used because of the increase in back pressure, and thus may result in an increased pain for patients (9, 14).

The origin and mechanism of the viscosity in antibody solution have been studied extensively by many scientists in the world (28–30). Three authors in Japan reviewed recently the origin of solution viscosity and concluded that the solution viscosity increases by the attraction and repulsion between the antibody molecules (30). The authors further described the use of small molecules such as amino acids and salts to control the viscosity of protein solution. More importantly, the authors provided a practical problem solution that would control the experimental behavior of protein solution viscosity. As concluded in this literature (30), the most frequently used viscosity-lowering excipients are arginine, sodium chloride and proline. In fact, multiple literatures as well as our formulation excipient analysis in Fig. 2 consistently concluded that arginine is the most widely used viscosity-lowering excipient because it may reduce both electrostatic
interaction and hydrophobic interaction between protein molecules (9, 30, 35).

Although the mechanism of viscosity in solution has been extensively studied, a prediction of high viscosity remains a challenge. The authors at University of Delaware and Amgen proposed that larger activation energies for protein–protein interactions correspond to larger activation energies for protein solution viscosity (η), and those became predictive with higher η value at higher protein concentrations (31, 32). This conclusion upon high viscosity prediction is largely consistent with the above-mentioned literature, which also shows protein–protein interactions (attraction and repulsion between protein molecules) as determinants of high viscosity in protein solutions (30).

A key risk for high-concentration antibody therapeutics is the antibody aggregation induced by high concentration as the antibody aggregation increases the immunogenicity of antibodies, leading to immune-mediated adverse effects. Thus, this risk has to be mitigated. The cause of antibody aggregation and the corresponding mitigation strategies have been widely studied and/or reviewed (38–39). The primary strategy for risk mitigation is to use surfactants such as polysorbates and Poloxamer 188. Indeed, our analysis data, as shown in Fig. 1, demonstrate that surfactant polysorbate 20 or polysorbate 80 is dominantly included in majority of 34 high concentration marketed products with a total of 31 (polysorbate 20 or polysorbate 80) formulations out of 34 formulations. The most commonly used surfactant is polysorbate 80 (22 out of 34) falling in a range of 0.1–2 mg/mL (i.e., 0.01–0.2%) followed by polysorbate 20 (8 out of 34) in a range of 0.1–4 mg/mL (i.e., 0.01–0.4%) and poloxamer 188 (2 out of 34, both at 0.5 mg/mL). The exact polysorbate type (i.e., either polysorbate 20 or polysorbate 80) is not specified in the disclosed formulation of Cimzia (Certolizumab pegol). Surprisingly, Synagis’ (Palivizumab) formulation does not contain any surfactant, and its formulation only contains chloride, glycine, and histidine, as shown in Table 1. In addition to lowering the viscosity, as reported earlier, arginine may serve as an ionic strength adjuster and aggregate reducer, and is also a promising excipient used in lyophilization formulation (33, 34, 37).

Another commonly used strategy to minimize antibody aggregation in solution is to make lyophilized formulation for antibodies at high concentration (41–44). Unique challenges, such as long reconstitution time for a lyophilized high antibody/protein concentration drug product, as well as solutions have been reviewed/reported (36).

From patient point of view, prefilled syringe (PFS), as a ready-to-use drug delivery system, is recognized as a convenient method to enable home self-administration, which can in turn provide considerable cost savings compared to dosing in a clinical setting. From industry point of view, overfill of 20–25% drug product in vial, especially with high-concentration formulations, forms the major costs. The PFS allows the overfilling drop down to 2–3%, a significant saving on the active and raw material cost. Furthermore, PFS, combining with high-concentration formulations, can also bring advantages such as patient compliance, dosing accuracy and reduction of wasted drug. Both greater dose precision and minimizing the drug waste can lead to smaller overage requirement, then further result in cost savings (45–47). For such reasons, PFS systems have been gaining strong acceptance in the market. As shown in Fig. 3, presentations of PFS alone and both PFS & Lyo account for 38% and 12% of all high-concentration dosage forms, respectively. Summing up together, PFS products have taken half (50% in total) of the market share in the high-concentration injectables market.

With the development of high-concentration formulations in PFS, one of the significant challenges that brings in the process, manufacturing and administration difficulties is again the high viscosity of the solution, which requires silicone oil coating to avoid high gliding forces. To ease the delivery of the contents, the design of plunger-barrel of PFS comes with the syringe barrels coated with silicone oil to provide the sufficient and uniform glide force to the plunger. Since silicone can leach into protein during storage of product in silicone-coated PFS, some syringe manufacturers developed new silicone-coating techniques with specialized silicone grade. Another unique challenge when uses PFS includes the extraction of contaminants (e.g., tungsten particles) because of the direct contact of antibodies with the surface of a plunger and a barrel lubricant (12). One literature demonstrates that the source of tungsten in PFS is the tungsten pin used in barrel manufacture to insert the needle (6).

And metals such as tungsten can leak from rubber stoppers. Metal chelators such as EDTA can assist formulators to resolve these problems. This extractable concerns may be overcome by replacing the rubber stoppers with the inert substances such as Teflon. Additionally, polymeric syringe systems have emerged to provide a solution for products that require the absence of silicone and tungsten. Thanks to the technical advances in PFS technology, more antibody drugs are expected to be formulated and brought to market with PFS (45–47).

Autojectors together with PFS are now commercially available to quite a few of the 34 antibodies such as Actemra (Tocilizumab), Aimovig (Erenumab), Zinbryta (Dacizumab), Nucala (Mepolizumab) and Simponi (Golimumab). The injection volume for most of these autojectors is limited up to only 1.0 mL. However, delivering increased volume with innovative autojectors is available to patients. For example, Amgen utilizes an innovative single use Pushtronex ® system (on-body infusor with prefilled cartridge) for its Repatha, in addition to its regular PFS. Pushtronex comprises a complex engine that moves a plunger inside a cylindrical barrel containing the drug, with the reservoir being either prefilled or filled by the user (9). This system can deliver 3.5 mL of Repatha solution (420 mg single dose) within 5 minutes. Considering SC injection volume may be now increased up to hundreds of milliliters, thanks to the above mentioned Halozymes’s hyaluronidase (rHuPH20), we expect that in the future more and more new autojectors with capability of delivering larger volumes of mAb solutions will be approved in the market to meet this unmet medical need.

Although an increasing number of mAbs are administered subcutaneously, many aspects of SC bioavailability of mAbs are still poorly understood. The major challenges of SC bioavailability of mAbs were already reviewed well in 2018, and the authors summarized the major
challenges including reliable models for predicting SC bioavailability of mAbs in humans. The scientists at Genentech and researchers at two universities in UK have recently made good progress in addressing these challenges. They established an in vitro model for predicting bioavailability of subcutaneously injected mAbs, and demonstrated the feasibility of this in vitro modeling strategy as a tool to identify drug and formulation properties that can define the performance of SC injected medicines (48). This model and approach may provide the potential for predicting clinical outcomes that could be useful for formulation selection and a first-in-human clinical dosing strategy. We expect that more progresses in SC bioavailability of mAbs will be further made in the years to come. In addition, the above-mentioned Merck’s AACR abstract reported Pembrolizumab (Keytruda’s) bioavailability after subcutaneous administration (11). Merck/MSD demonstrated in this abstract that the PK of pembrolizumab’s two SC formulations were similar with an estimated bioavailability of 64% (95% CI, 54–74); and this is consistent with the reported bioavailability of other SC monoclonal antibodies that dominantly range from 50 to 85% in humans (48).

It is understandable that SC is the dominant administration route for the high-concentration antibody products as high concentration is usually necessary to deliver desired dose in volume amenable to subcutaneous delivery. Although we do not fully understand why five high-concentration products are IV delivered, there are at least two potential reasons for IV administration. The first reason is high dose. For example, Trogarzo (Ibalizumab-uiyk) is administered intravenously as a single loading dose of 2000 mg followed by a maintenance dose of 800 mg every 2 weeks. Another example is Evkeeza (Evinacumab-dgnb) with a dose of 1200 mg. The second reason is that IV offers inline filters to address particle concerns. Although there are syringes equipped with inline filters, the use of them is not considered as convenient especially when viscosity is often an inherit characteristic of high-concentration products. Multiple antibody products (such as Aduhelm/Aducanumab-awwa) are indeed administered as IV via 0.2 or 0.22 micron inline filter.

As demonstrated in Table 1, 34 antibodies with high concentration (≥100 mg/mL), accounting for nearly one-third of the total FDA-approved antibody based drugs (not including Fc fusion protein), have been approved commercially by FDA as of October 2021. This indicates that achieving 100 mg/mL protein concentration in antibody formulation nowadays would not be much difficult within the biopharmaceutical industry. The highest protein concentration in solution among these 34 antibody drugs is 200 mg/mL. It is expected that therapeutic antibodies with higher than 200 mg/mL protein concentration will be approved in the future by the US FDA. The limitation to achieve such high protein concentration for a mAb may be partially due to the high viscosity. When the protein concentration is increased from 100 mg/mL or even from 50 mg/mL, the viscosity of mAb is typically increased exponentially. Regardless of the recent technical advances in high-concentration formulation, extremely high mAb concentration such as above 500 mg/mL, will still be very challenging to achieve (13). Some companies focusing upon new technology development of biologics formulation (e.g., Elektrofi) take advantage of such new technology—as using particle suspensions to make protein concentration reaching greater than 400 mg/mL without exceeding the viscosity limits while preserving the full activity of the biologic, as the company claimed at its website (elektrofi.com).

Interestingly, it is noted that all these 34 highly concentrated antibodies are either naked full length IgG or antibody fragments (scFv and Fab). No antibody drug conjugates (ADCs) are yet on the list as of to date. This is because of the special formulation challenges associated with ADCs such as stability of linker and solubility of the ADCs. In addition, all 11 ADC drug products approved by FDA so far are manufactured as lyophilized form at low protein concentration of the reconstituted ADC solutions, partially because of the above-mentioned stability and solubility issues (data resource: Drugs@FDA). Consequently, ADCs are unlikely to be administered subcutaneously (49, 50).

Taken together, we believe that high-concentration formulations of antibody drugs will be the future trend of therapeutic antibody formulation development, regardless the challenges encountered for highly concentrated protein formulations. We also believe that all these challenges and problems are resolvable, thanks to the new formulation technology advancement and the aid of SC Consortium.

ACKNOWLEDGEMENTS

The authors thank our colleague at WuXi Biologics, Dr. Sunny Zhang for the helpful discussion in revising the manuscript.

FUNDING STATEMENT

None.

CONFLICT OF INTEREST STATEMENT

Shawn Shouye Wang and Kin Ho are employees and shareholders of WuXi Biologics. Shawn Shouye Wang was the founding president, has been serving as a director in the Board of Directors for Chinese Antibody Society. Antibody Therapeutics is the official journal of Chinese Antibody Society. The authors report no other potential conflicts of interest for this work.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are openly available.

ETHICS AND CONSENT

Consent was not required.

ANIMAL RESEARCH

This is not applicable.
REFERENCES

1. Marks, L. The birth pangs of monoclonal antibody therapeutics. MAbs 2012; 4: 403–12.
2. Mullard, A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov 2021; 20: 7: 491–5.
3. Shire, SJ, Shahrokhi, Z, Liu, J. Challenges in the development of high protein concentration formulations. J Pharm Sci 2004; 93: 1390–402.
4. Sahin, E, Deshmukh, S. Challenges and considerations in development and manufacturing of high concentration biologics drug products. J Pharm Innov 2020; 15: 255–67.
5. Lutz, H, Arias, J, Zou, Y. High concentration biotherapeutic formulation and ultrafiltration: part 1 pressure limits. Biotechnol Prog 2017; 33: 113–24.
6. Shire, SJ. Development of delivery device technology to deal with the challenges of highly viscous mAb formulations at high concentration. In: Monoclonal Antibodies. Cambridge, UK: Elsevier; 2013, 153–62.
7. Gervasi, V, Agnol, RD, Cullen, S et al. Parenteral protein formulations: an overview of approved products within the European Union. Eur J Pharm Biopharm 2018; 131: 8–24.
8. Geskey, JM, Thomas, NJ, Brummel, GL. Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV). Biol Targets Ther 2007; 1: 33–43.
9. Strickler, RG, Lambert, WJ. A review of formulations of commercially available antibodies. J Pharm Sci 2021; 110(7): 2590–2608.e56.
10. Storoz, U. Extending the market exclusivity of therapeutic antibodies through dosage patents. MAbs 2016; 8: 841–7.
11. Jacobs, CR, Rapoport, BL, Cohen, GL et al. Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma. In: Proceedings of the 2021 Annual Meeting of the American Association for Cancer Research. AACR Annual Meeting 2021, 2021.
12. Kling, J. Highly concentrated protein formulations bio process finding solutions for the next generation of parenteral biologics. 2014.
13. Garidel, P, Kuhn, AB, Schäfer, L et al. Monoclonal antibodies: formulations how high is high? Eur J Pharm Biopharm 2017; 119: 533–60.
14. Basu, B, Dharamsi, A, Makwana, S et al. Prefilled syringes: an innovation in parenteral packaging. Int J Pharm Invest 2011; 1: 200.
15. Hu, P, Wang, J, Florian, J et al. Systematic review of device parameters and design of studies bridging biologic-device combination products using prefilled syringes and autoinjectors. AAPS J 2020; 22.
16. Bittner, B, Richter, W, Schmidt, J. Subcutaneous Administration of Biotherapeutics: an overview of current challenges and opportunities. Bio Drugs 2018; 32: 425–440.
17. Sacha, G, Rogers, JA, Miller, RL. Pre-filled syringes: a review of the history, manufacturing and challenges. Pharm Dev Technol 2015; 20: 1–11.
18. Yonedna, S, Torisu, T, Uchiyama, S. Development of syringes and vials for delivery of biologics: current challenges and innovative solutions. Expert Opin Drug Deliv 2021. 10.1080/17425247.2021.1853699.
19. Awwad, S, Angkawinitwong, U. Overview of antibody drug delivery. Pharmaceutics 2018; 10: 83.
20. Cui, Y, Cui, P, Chen, B et al. Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system. Drug Dev Ind Pharm 2017; 43: 519–30.
21. Viola, M, Sequeira, J, Seiça, R et al. Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control Release 2018; 286: 301–14.
22. Alves, NJ. Antibody conjugation and formulation. Antivir Ther 2018; 1: 33–9.
23. Collins, DS, Sánchez-Félix, M, Badkar, A et al. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. J Control Release 2020; 321: 475–82.
24. Badkar, AV, Gandhi, RB, Davis, SP et al. Subcutaneous delivery of high-dose/volume biologics: current status and prospect for future advancements. Drug Des Devel Ther 2021; 15: 159–70.
25. Weber, GC, Buhren, BA, Schrampf, H et al. Clinical applications of hyaluronidase. In: Advances in Experimental Medicine and Biology. New York LLC: Springer; 2019, Vol. 1148, 255–77.
26. Locke, KW, Daniel, CM, and Michael, JL. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug delivery 2019; 26(1): 98–106.
27. Tolba, MF, Elghazaly, H, Bousoik, E et al. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers. Clin translat oncol 2021; 10: 1979–1994.
28. Warnke, NW. Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. Eur J Pharm Biopharm 2011; 78: 208–12.
29. Tomar, DS, Kumar, S, Singh, SK et al. Molecular basis of high viscosity in concentrated antibody solutions: strategies for high concentration drug product development. MAbs 2016; 8: 216–28.
30. Inoue, N, Takai, E, Arakawa, T et al. Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations. Mol Pharm 2014; 11: 1889–96.
31. Woldeyes, MA, Qi, W, Razinkov, VI et al. Temperature dependence of protein solution viscosity and protein-protein interactions: insights into the origins of high-viscosity protein solutions. Mol Pharm 2020; 17: 4473–82.
32. Woldeyes, MA, Qi, W, Razinkov, VI et al. How well do low and high-concentration protein interactions predict solution viscosities of monoclonal antibodies? J Pharm Sci 2019; 108: 142–54.
33. Wang, S, Zhang, N, Hu, T et al. Viscosity-lowering effect of amino acids and salts on highly concentrated solutions of two IgG1 monoclonal antibodies. Mol Pharm 2015; 12: 4478–87.
34. Deokar, V, Sharma, A, Mody, R et al. Comparison of strategies in development and manufacturing of low viscosity, ultra-high concentration formulation for IgG1 antibody. J Pharm Sci 2020; 109: 3579–89.
35. Hong, T, Iwashita, K, Shiraki, K. Viscosity control of protein solution by small solutes: a review. Curr Protein Pept Sci 2017; 19: 746–58.
36. Stärtzel, P. Arginine as an excipient for protein freeze-drying: a mini review. J Pharm Sci 2018; 107: 960–7.
37. Kheddo, P, Golovanov, AP, Mellody, KT et al. The effects of arginine glutamate, a promising excipient for protein formulation, on cell viability: comparisons with NaCl. Toxicol In Vitro 2016; 33: 88–98.
38. Lundahl, MLE, Fogli, S, Colavita, PE et al. Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies. RSC Chem Biol 2021; 2(4): 1004–20.
39. Bauer, J, Mathias, S, Kube, S et al. Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain. MAbs 2020; 12(1): 1787121.
40. Cao, W, Krishnan, S, Ricci, M et al. Rational design of lyophilized high concentration protein formulations-mitigating the challenge of slow reconstitution with multidisciplinary strategies. Eur J Pharm Biotechnol 2013; 85: 287–93.
41. Gitter, JH, Grödholer, R, Presser, J et al. Pharmacuetics microwave-assisted freeze-drying of monoclonal antibodies: product quality aspects and storage stability. 10.3390/pharmaceutics11100674.
42. Bjošević, M, Seljak, KB, Trstenjak, U et al. Aggressive conditions during primary drying as a contemporary approach to optimise freeze-drying cycles of biopharmaceuticals. Eur J Pharm Sci 2018; 122: 292–302.
43. Isuzu, KI. Applications of freezing and freeze-drying in pharmaceutical formulations. In: Advances in Experimental Medicine and Biology. New York LLC: Springer; 2018, Vol. 1081, 371–83.
44. Larsen, BS, Skytte, J, Svang, AJ et al. Using dextran of different molecular weights to achieve faster freeze-drying and improved storage stability of lactate dehydrogenase. Pharm Dev Technol 2019; 24: 323–8.
45. Ingle, RG, Agarwal, AS. Prefilled syringe-a ready-to-use drug delivery system: A review. Expert Opin Drug Deliv 2014; 11: 1391–9.
46. Dimitrova, MN, Bee, JS, Lu, I et al. Development of prefilled syringe combination products for biologics. In: AAPS Advances in the Pharmaceutical Sciences Series. Berlin, Germany: Springer Verlag; 2018, Vol. 38, 203–24.
47. Shieu, W, Stauth, OB, Maa, YF. Filling of high-concentration monoclonal antibody formulations into pre-filled syringes:
investigating formulation-nozzle interactions to minimize nozzle clogging. *PDA J Pharm Sci Technol* 2015; **69**: 417–26.

48. Bown, HK, Bonn, C, Yohe, S et al. In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies. *J Control Release* 2018; **273**: 13–20.

49. Duerr, C, Friess, W. Antibody-drug conjugates—stability and formulation. *Eur J Pharm Biopharm* 2019; **139**: 168–76.

50. Singh, SK, Luisi, DL, Pak, RH. Antibody-drug conjugates: design, formulation and physicochemical stability. *Pharm Res* 2015; **32**: 3541–71.